ANIP Q3 2024 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q3 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$148M+12.5% YoY

Gross Profit

$85M57.5% margin

Operating Income

-$21M-13.8% margin

Net Income

-$24M-16.3% margin

EPS (Diluted)

$-1.27

QoQ Revenue Growth

+7.5%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

$8M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$857M

Stockholders' Equity

$431M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$148M	$132M	+12.5%
Gross Profit	$85M	$84M	+1.8%
Operating Income	-$21M	$18M	-214.3%
Net Income	-$24M	$10M	-343.1%

Revenue Segments

Generics, Established Brands, and Other

$92M62%

Rare Disease

$56M38%

Geographic Segments

UNITED STATES

$147M99%

Non-US

$1M1%